Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

2023 Annual Meeting | Industry Therapeutic Update from Novo Nordisk: Novel Approaches and Targets in AD and PD

Monday 04/24/23
06:00 PM - 09:00 PM EST Add To Calendar
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
Industry Therapeutic Update
Jeffrey Lee Cummings, MD, FAAN, Rhoda Au, PhD, Roger Barker, PhD, Sharon Cohen, MD, Rachel Dolhun, MD, Harini Sarva, MD, Harris Eyre, MD,PhD, Malu Gamez Tansey, PhD
General Neurology, Aging and Dementia, Aging, Dementia, Cognitive, and Behavioral Neurology, Movement Disorders
An interactive, discussion-based session that will aim to advance our understanding of Alzheimer's and Parkinson's disease pathology and patient-centered care.
The program will focus on upcoming treatment targets, opportunities in digital health technologies as well as clinical applications and other nonmedicinal aspects of Alzheimer's and Parkinson's disease management. We will further identify how brain health strategies can improve the lives of people living with neurodegenerative diseases.
Chair:
Jeffrey Cummings, M.D., Sc.D.
Speakers:
Rhoda Au, Ph.D.
Roger Barker, BA, MBBS, MRCP, PhD
Sharon Cohen, MD, FRCPC
Rachel Dolhun, M.D., DipABLM
Harris Eyre, M.D., Ph.D.
Malu Gamez Pansey Ph.D.
Harini Sarva. M.D.
Please note that no CME will be given by any accredited organization for attending. Additionally, Industry Therapeutic Program Content and the views expressed herein are those of the presenting corporate entity and not those of the AAN. These programs are not an part of the 2023 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research, use of pre-FDA drugs, or other research information that may be discussed. Industry Therapeutic Updates are industry events.
No CME available

Program Materials Program Evaluations

Event Timeline
06:00 PM - 09:00 PM EST Speaker Industry Therapeutic Update from Novo Nordisk: Novel Approaches and Targets in AD and PD
Faculty Disclosures
Jeffrey Lee Cummings, MD, FAAN Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ACADIA. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alkahest. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche/Genentech. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Green Valley. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Grifols. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Otsuaka. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for United Neuroscience. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Cummings has received research support from NIH. Dr. Cummings has received intellectual property interests from a discovery or technology relating to health care.
Sharon Cohen, MD The institution of Dr. Cohen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alnylam. The institution of Dr. Cohen has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. The institution of Dr. Cohen has received personal compensation in the range of $0-$499 for serving as a Consultant for Diamond Therapeutics Inc.. The institution of Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. The institution of Dr. Cohen has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for ProMIS Neurosciences Inc.. The institution of Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for RetiSpec Inc.. The institution of Dr. Cohen has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for College of Physicians and Surgeons of Ontario. The institution of Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CME Outfitters. The institution of Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Integritas. The institution of Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for DBK Med.
Rhoda Au, PhD Dr. Au has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Au has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Au has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Au has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NovoNordisk. Dr. Au has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GSK. Dr. Au has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. Dr. Au has received publishing royalties from a publication relating to health care. Dr. Au has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant with Davos Alzheimer's Collaborative. Dr. Au has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant with High Lantern.
Roger Barker, PhD Roger Barker, PhD has nothing to disclose.
Rachel Dolhun, MD Dr. Dolhun has received personal compensation for serving as an employee of The Michael J. Fox Foundation.
Harini Sarva, MD Dr. Sarva has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurocrine. Dr. Sarva has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novo Nordisk. Dr. Sarva has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novo Nordisk. The institution of Dr. Sarva has received research support from Insightec. The institution of Dr. Sarva has received research support from NeuroNext. The institution of Dr. Sarva has received research support from Neuroderm. The institution of Dr. Sarva has received research support from Covance. The institution of Dr. Sarva has received research support from Prevail. The institution of Dr. Sarva has received research support from Bluerock Therapeutics. The institution of Dr. Sarva has received research support from Biogen. The institution of Dr. Sarva has received research support from Roche. The institution of Dr. Sarva has received research support from National Institute of Aging. The institution of Dr. Sarva has received research support from Michael J Fox Foundation. The institution of Dr. Sarva has received research support from Novo Nordisk. Dr. Sarva has received research support from Bukwang. The institution of Dr. Sarva has received research support from Bial.
Harris Eyre, MD,PhD No disclosure on file
Malu Gamez Tansey, PhD No disclosure on file